Abstract #3074

Radiomics approach in differentiating the true progression from pseudoprogression in malignant gliomas treated with concurrent radiotherapy and temozolomide chemotherapy

Yan Bai^1,2, Jing Zhou^1,2, Wei Wei^1,2, Yusong Lin³, and Meiyun Wang^1,2

¹Department of Radiology, Henan Provincial People's Hospital, Zhengzhou, China, ²Henan Key Laboratory for Medical Imaging of Neurological Diseases, Zhengzhou, China, ³Cooperative Innovation Center of Internet Healthcare & School of Software and Applied Technology, Zhengzhou University, Zhengzhou, China

The conventional magnetic resonance imaging could not confirm the enhancing lesion in malignant gliomas after the standard postsurgical treatment is due to the ture progression or pseudoprogression. The radiomics model based on the selected magnetic resonance imaging features was established to predict the ture progression and pseudoprogression. The radiomics model yielded the AUC value of 0.875 and 0.821 for the train set and test set, respectively. The radiomics model based on the selected contrast-enhanced T1WI features is useful in differentiating the true progression from pseudoprogression in malignant gliomas treated with concurrent radiotherapy and temozolomide chemotherapy after the surgical resection.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.